In the June quarter, Mumbai-based Sun Pharmaceutical Industries posted a 43 per cent rise in net profits to Rs 2,061 crore. The consolidated net profit was Rs 1,444 crore. Revenue from operation surges 9.7 per cent to Rs 10,762 crore and rose to Rs 9,719 crore last year. In the last quarter of 2021-22, the revenue had posted at Rs 9,447 crore.

It has reported an Ebitda (earnings before interest, tax, depreciation and amortization) of Rs 2,884 crore (including other operating revenues), with the Ebitda margin at 26.8 per cent. This is lower than 28.7 per cent in Q1FY22.

“For Q1, all our businesses recorded good growth, driven by sustained scale-up for our speciality business and all-around growth across markets. Speciality business has grown by 29 per cent, driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than the market, leading to increased market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global speciality business, growing all our businesses and improving our market share,” said the company’s managing director Dilip Shanghvi.